Danisco
CompanyDenmark
Danisco develops 2 assets, the furthest in phase 3 (Menatetrenone in osteoporosis). Mostly supplement; based in Denmark.
- 2
- Assets
- Furthest stage
- Phase 3
- 8
- Trials
- 12
- Signals
Pipeline
2Cofactor for gamma-glutamyl carboxylase essential for activating vitamin K-dependent proteins
Phase 3, Supplement, osteoporosis, postmenopausal osteoporosis
Flavanol that improves endothelial and vasodilatory function
Phase 2, no development reported, Supplement, borderline hypertension, Becker muscular dystrophy (Phase 1)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials8
- Signals20
- Similar companies6